diseases

Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is…

3 days ago

Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies

Collaboration in Singapore aims to further expand the broad potential of Life Bio’s Partial Epigenetic Reprogramming Platform as part of…

4 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical…

6 days ago

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with…

1 week ago

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

3 weeks ago

Immutheras Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz,…

3 weeks ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 19:30 ET  | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…

1 month ago

Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders

Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially…

1 month ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025 01:00 ET  | Source: argenx SE June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX),…

2 months ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare…

2 months ago